本文選題：腦膠質(zhì)瘤 + 藥敏實(shí)驗(yàn)��； 參考：《桂林醫(yī)學(xué)院》2014年碩士論文

【摘要】：目的：運(yùn)用MTT法測定腦膠質(zhì)細(xì)胞瘤體外對化療藥物的敏感性，，為臨床個性化化療方案的設(shè)計提供參考。方法：取術(shù)中快速冰凍病理檢查及術(shù)后常規(guī)病理檢查均證實(shí)為膠質(zhì)瘤并成功原代培養(yǎng)22例標(biāo)本，與腫瘤化療藥多柔比星（Doxorubicin, ADM)、卩比柔比星（Pirarubicin，THP)、卡莫司汀(Carmustine, BCNU)、替尼泊苷(Teniposide, Vm-26)、順鈾(cis-Dichlorodiamineplatinum, DDP)的臨床常用濃度(按血團(tuán)峰值濃度（PPC)配制）作用72小時，MTT法檢測不同腫瘤個體對不同化療藥物及其相互兩兩配對組合的敏感和耐藥情況。結(jié)果：22例臨床腦膠質(zhì)瘤標(biāo)本對5種化療藥物單獨(dú)用藥的敏感性從高到低依次為Vm-26 BCNU THPADM DDP，22例臨床腦膠質(zhì)瘤標(biāo)本對5化療藥物兩兩配對的敏感性從高到低依次為THP+Vm-26 BCNU+Vm-26 ADM+Vm-26 Vm-26+DDP THP+BCNU ADM+BCNU BCNU+DDP THP+DDP ADM+DDP THP+ADM。年齡、性別對大多數(shù)藥物敏感率無影響，腫瘤分級只對部分藥物敏感率有影響。結(jié)論：MTT法體外藥敏實(shí)驗(yàn)是一種簡便、經(jīng)濟(jì)、準(zhǔn)確的藥敏實(shí)驗(yàn)，對于指導(dǎo)臨床合理地制定個體化化療方案有著重要的作用，5種常用的抗腫瘤藥物均有耐藥的情況，敏感性高低不一，單獨(dú)用藥則以Vm-26效果最好，而腫瘤細(xì)胞耐藥性最強(qiáng)的則是DDP。但經(jīng)過將化療藥物兩兩配對聯(lián)合用藥能明顯提高殺瘤效果，其中以Vm-26+THP的組合效果最為明顯，而將THP+ADM進(jìn)行實(shí)驗(yàn)并不能提高藥物敏感性，和單獨(dú)用藥無明顯差別。
[Abstract]:Objective: to determine the sensitivity of glioma of brain to chemotherapeutic drugs by MTT method in order to provide reference for the design of individualized chemotherapy regimen. Methods: 22 cases of glioma were confirmed by intraoperative frozen pathological examination and routine pathological examination after operation and successfully cultured in primary culture. A 72 hour assay was used to detect the clinical concentrations of docorubicin, ADMN, pirarubicinine, Carmustine, BCNU, Teniposide, Vm-26N, cis-Dichodiamplatine inum (DDPum) in different tumor individuals by 72 hours of treatment with Doxorubicin, ADMN, pirarubicinine, Carmostin, Carmustine, Teniposide, Vm-26N, cis-Dichodiamplatineinum (DDPumn), which were prepared according to the peak blood mass concentration (PPCMTT). Sensitivity and resistance of chemotherapeutic agents and their paired combinations. Results the sensitivity of 22 brain glioma specimens to 5 chemotherapeutic drugs was from high to low. The sensitivity of 22 cases of glioma patients with clinical brain glioma was from high to low, from high to low to that of THP Vm-26. BCNU Vm-26 ADM Vm-26 Vm-26 DDP THP BCNU ADM BCNU BCNU DDP THP DDP ADM DDP THP ADM. Age and sex had no effect on most drug sensitivity, but tumor grading had no effect on drug sensitivity. Conclusion the in vitro drug sensitivity test with the method of: MTT is a simple, economical and accurate drug sensitivity test. It has an important role in guiding clinical rational formulation of individualized chemotherapy regimen. All of the five commonly used antitumor drugs are resistant to drugs. The sensitivity of Vm-26 was the best, and the drug resistance of tumor cells was the strongest. But the combination of two and two chemotherapeutic drugs can obviously improve the effect of tumor killing, among which the combination of Vm-26 THP is the most obvious, but the experiment of THP ADM can not improve the drug sensitivity, and there is no significant difference between the two groups.
【學(xué)位授予單位】：桂林醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R739.41

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 陳忠平;張俊平;;惡性腦腫瘤化療新動態(tài):分子靶向治療[J];中國神經(jīng)腫瘤雜志;2005年01期

2 陳新峰;楊菁;;用MTT法進(jìn)行白血病體外藥物敏感性檢測的臨床意義[J];福建醫(yī)科大學(xué)學(xué)報;2009年02期

3 陳建文,張俊平,程金建,陳建良,史鴻瀏,張俊英,牟永告,張湘衡,周旺寧,賽克,陳忠平;體外藥敏試驗(yàn)指導(dǎo)的惡性腦膠質(zhì)瘤預(yù)見性化療[J];廣東醫(yī)學(xué);2005年09期

4 關(guān)良,張紀(jì);腦惡性膠質(zhì)瘤的瘤內(nèi)化療[J];軍事醫(yī)學(xué)科學(xué)院院刊;2001年04期

5 方立仁;莫萬彬;;鹽酸多柔比星控緩釋局部化療在腦膠質(zhì)瘤術(shù)后治療中的療效[J];求醫(yī)問藥(下半月);2013年01期

6 劉金龍,陳碩朗,林佳平,金華偉,吳新建,黃權(quán),陳曉雷;膠質(zhì)瘤顯微手術(shù)切除加術(shù)中間質(zhì)化療的臨床效果[J];中華顯微外科雜志;2003年02期

7 鄧萬凱;黃書嵐;;惡性膠質(zhì)瘤術(shù)后應(yīng)用替莫唑胺化療聯(lián)合放療的臨床觀察[J];腫瘤防治研究;2006年10期

8 張偉;江濤;袁芳;李桂林;董麗萍;徐立新;韓明;崔云;;腦膠質(zhì)瘤組織培養(yǎng)化療藥物敏感性的研究[J];中國微侵襲神經(jīng)外科雜志;2007年04期

9 張熠丹;馬文斌;王任直;;惡性膠質(zhì)瘤化療的過去、現(xiàn)在和未來[J];協(xié)和醫(yī)學(xué)雜志;2012年03期

本文編號：1877752